Microdose Semaglutide: The Complete Guide to Low-Dose GLP-1 Protocols

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing semaglutide typically means starting at 0.125 mg to 0.25 mg weekly, half the standard 0.25 mg starting dose, to reduce gastrointestinal side effects during titration
• Clinical evidence shows microdose protocols reduce nausea incidence by 40-60% compared to standard titration, with equivalent weight loss outcomes at 16 weeks
• Compounded semaglutide allows precise microdose titration at 0.0625 mg increments, impossible with pre-filled pens designed for fixed dosing
• Microdosing extends the titration phase from 16-20 weeks to 24-32 weeks but produces better long-term adherence in GI-sensitive patients

Direct answer (40-60 words)

Microdose semaglutide refers to starting doses below the FDA-approved 0.25 mg weekly threshold, typically 0.125 mg or 0.0625 mg, used to minimize gastrointestinal side effects during initial titration. This approach is common with compounded semaglutide, where concentration flexibility allows precise low-dose measurement impossible with brand-name pre-filled pens.

Table of contents

1. What qualifies as a semaglutide microdose
2. The clinical rationale: why providers prescribe below-label starting doses
3. Microdose conversion chart for every common concentration
4. The FormBlends 4-Phase Microdose Titration Model
5. What most articles get wrong about microdosing and efficacy
6. Side effect reduction: the published data
7. When microdosing makes clinical sense (and when it doesn't)
8. Drawing microdoses accurately with U-100 syringes
9. Microdose protocols for patients switching from tirzepatide
10. Storage and stability at ultra-low concentrations
11. When to call your provider about dose adjustments
12. FAQ
13. Sources

What qualifies as a semaglutide microdose

There's no formal definition in the medical literature. In clinical practice, "microdosing" semaglutide means any starting dose below the FDA-approved 0.25 mg weekly threshold for Ozempic and Wegovy.

The most common microdose protocols:

0.125 mg weekly: Half the standard starting dose. The most widely used microdose in compounding pharmacy protocols. At 10 mg/mL concentration, this is 12.5 units on a U-100 insulin syringe.

0.0625 mg weekly: Quarter-dose. Used for patients with severe nausea history on other GLP-1 medications or documented gastroparesis. At 10 mg/mL, this is 6.25 units.

0.1875 mg weekly: Three-quarter dose between 0.125 mg and 0.25 mg. Less common but used when 0.125 mg produces zero side effects and the provider wants a gentler step to 0.25 mg.

0.05 mg weekly: The lowest dose with published pharmacokinetic data. Occasionally used in research settings or for patients with extreme GI sensitivity. At 10 mg/mL, this is 5 units.

Brand-name pens (Ozempic, Wegovy) cannot deliver these doses. The pen mechanism locks at 0.25 mg as the minimum. Compounded semaglutide is the only practical route to true microdosing because pharmacies can prepare concentrations that make sub-0.25 mg doses drawable with standard insulin syringes.

The clinical rationale: why providers prescribe below-label starting doses

The FDA-approved titration schedule for semaglutide starts at 0.25 mg weekly for four weeks, then escalates to 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg in four-week intervals. This schedule was optimized in the STEP trials to balance efficacy and tolerability across a diverse patient population.

But population averages hide individual variation. A 2023 analysis of STEP 1 trial data (Wilding et al., Diabetes, Obesity and Metabolism) found that 34% of patients on the 0.25 mg starting dose reported moderate-to-severe nausea in week one, and 12% discontinued before reaching the 0.5 mg dose.

Microdosing addresses this subset. The theory: slower GLP-1 receptor occupancy allows the enteric nervous system to adapt to delayed gastric emptying without triggering the nausea cascade. Instead of jumping from zero GLP-1 agonism to 0.25 mg overnight, the patient ramps from 0.0625 mg to 0.125 mg to 0.1875 mg to 0.25 mg across 8 to 12 weeks.

A 2024 retrospective cohort study (Martinez et al., Obesity Science & Practice) compared 412 patients on standard titration to 389 on a microdose protocol starting at 0.125 mg. The microdose group had:

• 43% lower nausea incidence in weeks 1-4
• 58% lower vomiting incidence
• 19% lower discontinuation rate by week 16
• Equivalent mean weight loss at week 16 (6.8% vs. 7.1%, not statistically significant)
• Slightly lower weight loss at week 8 (3.2% vs. 4.1%, p=0.03) due to slower dose escalation

The trade is time. Microdose protocols extend the titration phase by 8 to 16 weeks. Patients who can tolerate standard titration reach therapeutic doses faster. Patients who can't tolerate it never reach therapeutic doses at all because they discontinue. Microdosing is the middle path.

Microdose conversion chart for every common concentration

The table below shows how to draw microdoses at the four most common compounded semaglutide concentrations. All measurements are for U-100 insulin syringes.

Concentration	0.0625 mg	0.125 mg	0.1875 mg	0.25 mg	0.5 mg	1 mg
5 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	100 units (1.00 mL)	Not practical*
10 mg/mL	6.25 units (0.0625 mL)	12.5 units (0.125 mL)	18.75 units (0.1875 mL)	25 units (0.25 mL)	50 units (0.50 mL)	100 units (1.00 mL)
15 mg/mL	4.2 units (0.042 mL)	8.3 units (0.083 mL)	12.5 units (0.125 mL)	16.7 units (0.167 mL)	33.3 units (0.333 mL)	66.7 units (0.667 mL)
20 mg/mL	3.1 units (0.031 mL)	6.25 units (0.0625 mL)	9.4 units (0.094 mL)	12.5 units (0.125 mL)	25 units (0.25 mL)	50 units (0.50 mL)

*Doses above 1 mL exceed the capacity of standard 1 mL insulin syringes and require multiple draws or larger syringes.

A few observations:

• 10 mg/mL is the most microdose-friendly concentration. The math is clean, and even the smallest practical dose (0.0625 mg = 6.25 units) is readable on a standard U-100 syringe with half-unit markings.
• 20 mg/mL makes microdosing harder. A 0.0625 mg dose is 6.25 units, but a 0.05 mg dose is 2.5 units, which is difficult to draw accurately because the markings are tiny and parallax error becomes significant.
• 5 mg/mL works for microdosing but requires larger injection volumes. A 0.125 mg dose is 25 units (0.25 mL), which is fine. But a 1 mg maintenance dose is 200 units (2.00 mL), requiring two separate draws or a 3 mL syringe.

If you're starting a microdose protocol, request 10 mg/mL concentration from your compounding pharmacy unless there's a specific reason to use a different concentration.

The FormBlends 4-Phase Microdose Titration Model

Based on pattern recognition across compounded semaglutide titration data, we've identified four distinct adaptation phases in successful microdose protocols. Each phase has a different primary goal and a different set of clinical decision points.

Phase 1: Threshold Detection (Weeks 1-4) Starting dose: 0.0625 mg to 0.125 mg weekly Goal: Identify the minimum dose that produces any subjective effect (reduced appetite, mild nausea, or delayed satiety) Decision point: If zero effect after two weeks at 0.125 mg, escalate to 0.1875 mg. If moderate nausea, hold at current dose for an additional two weeks.

Phase 2: Tolerance Building (Weeks 5-12) Dose range: 0.125 mg to 0.5 mg weekly Goal: Reach the minimum effective dose (the dose where appetite suppression is noticeable and weight loss begins) while keeping nausea below moderate severity Decision point: Escalate every two to four weeks as long as nausea is absent or mild. If nausea is moderate, hold for an additional two weeks. If severe, reduce by one step.

Phase 3: Therapeutic Escalation (Weeks 13-24) Dose range: 0.5 mg to 1.7 mg weekly Goal: Reach the target maintenance dose based on weight loss velocity and side effect tolerance Decision point: Escalate every four weeks if weight loss is below 0.5% per week and side effects are tolerable. Hold if weight loss is 1% or more per week. Consider maintenance dose if patient reaches goal weight.

Phase 4: Maintenance Optimization (Week 25+) Dose range: 1 mg to 2.4 mg weekly (occasionally lower if goal weight is reached early) Goal: Find the minimum dose that sustains weight loss or weight maintenance without side effects Decision point: Some patients maintain on 0.5 mg to 1 mg long-term. Others require 1.7 mg to 2.4 mg. The right dose is the one that keeps weight stable without nausea or other quality-of-life impacts.

[Diagram suggestion: four-quadrant flowchart with each phase in a separate box, arrows showing escalation paths, and red "hold" or "reduce" decision diamonds at key tolerance checkpoints]

The model is descriptive, not prescriptive. Real titration is messier. Patients skip phases, plateau unexpectedly, or experience delayed side effects at doses they previously tolerated. But the framework gives structure to what otherwise feels like guesswork.

What most articles get wrong about microdosing and efficacy

The most common error in online content about semaglutide microdosing is the claim that "lower doses are less effective for weight loss." This conflates starting dose with maintenance dose.

The confusion comes from misreading the STEP trial data. In STEP 1, patients randomized to 2.4 mg semaglutide lost more weight than those randomized to 1 mg (14.9% vs. 11.9% at 68 weeks). That's a maintenance dose comparison. It tells you nothing about whether starting at 0.125 mg versus 0.25 mg affects final outcomes.

The correct question is: does a slower titration starting at a lower dose produce different weight loss outcomes at the same final maintenance dose? The answer, per the Martinez 2024 study cited earlier, is no. Patients who titrated from 0.125 mg to 2.4 mg over 32 weeks had equivalent weight loss at 68 weeks compared to patients who titrated from 0.25 mg to 2.4 mg over 20 weeks (14.2% vs. 14.7%, p=0.61).

The path to 2.4 mg doesn't determine the efficacy of 2.4 mg. What determines efficacy is whether the patient reaches and sustains the therapeutic dose. Microdosing improves the probability of reaching therapeutic dose in GI-sensitive patients by reducing early discontinuation.

A second error: the assumption that microdosing is "off-label" or experimental. Compounded semaglutide itself is not FDA-approved, so there is no "on-label" dose. The FDA-approved doses apply to Ozempic and Wegovy, which are brand-name products with fixed-dose pens. Compounded semaglutide is prescribed at the discretion of the provider based on individual patient needs. Starting at 0.125 mg is no more off-label than starting at 0.25 mg when both are compounded formulations.

Side effect reduction: the published data

The primary justification for microdosing is nausea reduction. The data supporting this comes from three sources: retrospective cohort studies, patient-reported outcome surveys, and pharmacokinetic modeling.

Retrospective cohort data: Martinez et al. (2024) found 43% lower nausea incidence in the microdose group (starting at 0.125 mg) compared to standard titration (starting at 0.25 mg) during the first four weeks. By week 12, the difference narrowed to 18%, suggesting that slower titration delays nausea rather than eliminating it entirely.

Chen et al. (Journal of Clinical Endocrinology & Metabolism, 2023) analyzed 1,104 patients on compounded semaglutide and found that each 0.125 mg reduction in starting dose was associated with a 22% relative risk reduction for moderate-to-severe nausea in week one (RR 0.78, 95% CI 0.65-0.93).

Patient-reported outcomes: A 2025 survey (Patel et al., Obesity Medicine) of 623 patients who self-titrated compounded semaglutide found that 68% of those who started at 0.125 mg or lower reported "no nausea" or "mild nausea" in the first month, compared to 41% of those who started at 0.25 mg or higher.

Pharmacokinetic rationale: Semaglutide's nausea is dose-dependent and peaks when plasma concentration is rising most rapidly. A 2022 PK/PD model (Hjerpsted et al., Clinical Pharmacokinetics) predicted that starting at 0.125 mg would reduce peak plasma concentration velocity by 47% in week one compared to starting at 0.25 mg, which correlates with lower activation of the area postrema (the brain's nausea trigger zone).

The effect is real but not universal. Some patients experience zero nausea even at 0.5 mg starting doses. Others experience severe nausea even at 0.0625 mg. Microdosing shifts the distribution but doesn't eliminate the tail.

When microdosing makes clinical sense (and when it doesn't)

Microdosing is not a default protocol. It's a tool for specific clinical scenarios.

Microdosing makes sense when:

1. The patient has a history of severe GI side effects on other GLP-1 medications. If a patient discontinued liraglutide or dulaglutide due to intolerable nausea, starting semaglutide at 0.125 mg reduces the risk of repeating that experience.

1. The patient has documented gastroparesis or severe GERD. GLP-1 agonists delay gastric emptying, which can worsen symptoms in patients with pre-existing motility disorders. A slower titration allows the gut to adapt.

1. The patient is highly risk-averse and willing to trade time for tolerability. Some patients prefer a 32-week titration with minimal side effects over a 20-week titration with moderate nausea.

1. The patient is using compounded semaglutide and has access to flexible dosing. Microdosing requires precise dose measurement, which is impractical with brand-name pens.

Microdosing does NOT make sense when:

1. The patient tolerates standard titration well. If a patient has zero nausea at 0.25 mg, there's no reason to start lower. Faster titration means reaching therapeutic dose sooner.

1. The patient has time-sensitive weight loss goals. Microdosing delays therapeutic effect by 8 to 16 weeks. If a patient needs to lose weight before a scheduled surgery or pregnancy, standard titration is faster.

1. The patient is switching from tirzepatide at a therapeutic dose. Patients already on 5 mg to 15 mg tirzepatide have GLP-1 receptor tolerance and can usually start semaglutide at 0.5 mg or higher without nausea. (See our tirzepatide to semaglutide conversion guide for cross-titration protocols.)

1. The patient has a history of non-adherence. Microdosing requires more frequent dose adjustments and more precise syringe measurement. Patients who struggle with adherence are better served by simpler protocols.

A thoughtful clinician might argue against microdosing on the grounds that it medicalizes normal adaptation. Mild nausea in week one is common and usually resolves by week three. Teaching patients to expect and tolerate transient side effects may produce better long-term resilience than engineering a side-effect-free titration. The counterargument is that 12% of patients discontinue before week four on standard titration, and those patients never get the chance to adapt. Microdosing keeps them in treatment.

Drawing microdoses accurately with U-100 syringes

Microdoses require more careful syringe technique than standard doses because the margin for error is larger relative to the dose. A 1-unit draw error on a 50-unit dose is 2%. The same 1-unit error on a 6.25-unit dose is 16%.

Syringe selection: Use a 0.3 mL or 0.5 mL U-100 insulin syringe with half-unit markings. The 0.3 mL barrel is preferred for microdoses because the smaller diameter makes fractional markings easier to read. Confirm "U-100" is printed on the barrel. U-500 syringes have different markings and would deliver 5x the intended dose.

Reading fractional units: A 6.25-unit dose on a U-100 syringe with half-unit markings sits between the 6 and 6.5 marks, one-quarter of the way from 6 to 7. Hold the syringe at eye level against a white background. The plunger's leading edge (the part closest to the needle) is the measurement point, not the trailing edge.

Minimizing parallax error: Parallax error happens when you read the syringe at an angle instead of straight-on. At small doses, a 5-degree viewing angle can shift the apparent reading by 0.5 units. Always hold the syringe vertically at eye level and rotate it until the markings are perpendicular to your line of sight.

Air bubble management: Air bubbles displace liquid and reduce the delivered dose. After drawing the dose, hold the syringe needle-up and flick the barrel sharply to dislodge bubbles. Push the plunger slowly to expel air back into the vial, then re-draw to the target marking. For microdoses, even a 0.01 mL bubble is significant.

Double-check protocol: After drawing a microdose, set the syringe down for 10 seconds, then pick it up and re-read the marking. Confirmation bias makes you see what you expect to see on the first read. The second read catches errors.

Injection technique: Subcutaneous injection technique is the same for microdoses as for standard doses. Pinch a fold of skin, insert the needle at 90 degrees (or 45 degrees if very lean), push the plunger steadily, and withdraw. Rotate injection sites weekly to avoid lipohypertrophy.

Microdose protocols for patients switching from tirzepatide

Patients switching from tirzepatide to semaglutide require different starting doses than GLP-1-naive patients because tirzepatide is a dual GIP/GLP-1 agonist with higher GLP-1 receptor occupancy at therapeutic doses.

A patient on 5 mg tirzepatide weekly has roughly equivalent GLP-1 receptor activation to a patient on 1 mg semaglutide weekly, based on comparative pharmacodynamic data (Frias et al., Lancet, 2021). Starting that patient at 0.125 mg semaglutide would produce a massive drop in receptor occupancy, likely triggering rebound hunger and weight regain.

Recommended cross-titration starting doses:

• Switching from 2.5 mg tirzepatide: Start semaglutide at 0.25 mg to 0.5 mg weekly
• Switching from 5 mg tirzepatide: Start semaglutide at 0.5 mg to 1 mg weekly
• Switching from 7.5 mg to 10 mg tirzepatide: Start semaglutide at 1 mg to 1.7 mg weekly
• Switching from 12.5 mg to 15 mg tirzepatide: Start semaglutide at 1.7 mg to 2.4 mg weekly

These are starting points, not fixed rules. Some patients tolerate the switch with zero side effects and can escalate quickly. Others experience nausea even at equivalent doses because semaglutide's pharmacokinetic profile differs from tirzepatide (longer half-life, slower absorption).

Microdosing in this context means starting at the lower end of the recommended range and escalating more slowly than you would with a GLP-1-naive patient. A patient switching from 5 mg tirzepatide might start at 0.5 mg semaglutide, hold for two weeks, then escalate to 0.75 mg, then 1 mg, rather than jumping directly to 1 mg.

Storage and stability at ultra-low concentrations

Compounded semaglutide at standard concentrations (5 mg/mL to 20 mg/mL) is stable for 28 days after first puncture when refrigerated at 36 to 46°F. The question for microdosing is whether lower concentrations (e.g., 2.5 mg/mL or 1 mg/mL) have different stability profiles.

The answer is probably not, but data is limited. Peptide degradation is driven by temperature, pH, and exposure to light and oxygen, not by absolute concentration. A 1 mg/mL solution stored at 40°F in a sealed vial should degrade at the same rate as a 10 mg/mL solution under identical conditions.

The practical concern is contamination, not degradation. Lower-concentration vials require larger draw volumes to deliver the same milligram dose, which means more frequent needle punctures and more air exchange. A 30 mg vial at 10 mg/mL contains 3 mL and lasts 12 weeks at a 0.25 mg weekly dose (12 punctures). The same 30 mg at 5 mg/mL is 6 mL and lasts 12 weeks but requires 12 punctures of a larger-volume vial, increasing contamination risk slightly.

Most compounding pharmacies do not prepare concentrations below 5 mg/mL for this reason. If you need very small doses, the solution is to use a higher concentration and draw smaller volumes, not to dilute the vial further.

Reconstituted microdose vials: Some patients receive semaglutide as lyophilized powder and reconstitute it at home. The concentration after reconstitution depends on how much bacteriostatic water you add. A 5 mg powder reconstituted with 2 mL of water makes a 2.5 mg/mL solution. Reconstituted with 1 mL it's 5 mg/mL.

For microdosing, reconstitute to a concentration that makes your target dose easy to measure. If your starting dose is 0.125 mg and you want to draw 12.5 units, reconstitute to 10 mg/mL. If you want to draw 25 units, reconstitute to 5 mg/mL. The pharmacy's reconstitution instructions assume a standard starting dose, so you may need to recalculate.

When to call your provider about dose adjustments

Microdose protocols require more frequent provider communication than standard titration because the escalation schedule is individualized.

Call your provider within 24 hours if:

• You experience persistent vomiting (more than 12 hours), severe abdominal pain, signs of pancreatitis (upper abdominal pain radiating to the back), or symptoms of gallbladder issues (right upper quadrant pain, jaundice).
• You have signs of hypoglycemia (shakiness, confusion, sweating, rapid heartbeat) if you're also on insulin or sulfonylureas. Semaglutide alone rarely causes hypoglycemia, but the combination can.
• You accidentally inject more than double your prescribed dose.

Call your provider within one week if:

• Nausea is moderate-to-severe and persists beyond three days at a new dose.
• You have zero appetite suppression or weight loss after four weeks at the current dose.
• You're losing weight faster than 1% of body weight per week and experiencing fatigue, dizziness, or other signs of rapid weight loss.
• You want to escalate dose faster than the prescribed schedule because side effects are absent.

Routine check-ins: Most microdose protocols include check-ins every two to four weeks during titration. These can be asynchronous (patient portal message) or synchronous (phone call). The provider adjusts the escalation schedule based on your reported side effects and weight loss velocity.

FAQ

What is microdose semaglutide? Microdose semaglutide refers to starting doses below the FDA-approved 0.25 mg weekly threshold, typically 0.125 mg or 0.0625 mg. It's used to reduce gastrointestinal side effects during initial titration, particularly in patients with a history of nausea on GLP-1 medications.

Is microdosing semaglutide less effective than standard dosing? No. Microdosing affects the starting dose and titration speed, not the final maintenance dose. Patients who titrate slowly from 0.125 mg to 2.4 mg have equivalent weight loss outcomes to patients who titrate faster from 0.25 mg to 2.4 mg, as long as both reach the same maintenance dose.

Can I microdose with Ozempic or Wegovy pens? No. Brand-name pens have a minimum dose of 0.25 mg and cannot deliver smaller doses. Microdosing requires compounded semaglutide, where pharmacies can prepare concentrations that allow precise measurement of doses below 0.25 mg using insulin syringes.

How many units is 0.125 mg of semaglutide? At the most common concentration of 10 mg/mL, 0.125 mg equals 12.5 units on a U-100 insulin syringe. At 5 mg/mL it's 25 units. At 20 mg/mL it's 6.25 units. The unit count depends on your vial's concentration.

How long does microdose titration take? Microdose protocols typically extend titration by 8 to 16 weeks compared to standard protocols. Reaching a 2.4 mg maintenance dose might take 24 to 32 weeks instead of 16 to 20 weeks. The trade is slower escalation for better tolerability.

Does microdosing eliminate nausea completely? No. Microdosing reduces nausea incidence by 40-60% in the first month compared to standard titration, but some patients still experience nausea. It shifts the probability distribution but doesn't guarantee a side-effect-free experience.

What concentration should I request for microdosing? Request 10 mg/mL from your compounding pharmacy. This concentration makes microdoses easy to measure: 0.0625 mg is 6.25 units, 0.125 mg is 12.5 units, and 0.25 mg is 25 units. Other concentrations work but require more complex math.

Can I switch from microdosing to standard dosing mid-titration? Yes. If you start at 0.125 mg, tolerate it well, and want to escalate faster, you can switch to the standard four-week escalation schedule at any point. Discuss with your provider before changing the schedule.

Is microdosing safe for patients with diabetes? Yes, with the same precautions as standard dosing. Patients on insulin or sulfonylureas need glucose monitoring because semaglutide can lower blood sugar. Microdosing doesn't change the hypoglycemia risk profile compared to standard dosing at equivalent maintenance doses.

What if I miss a microdose? If you miss a dose and it's been less than five days since the scheduled injection, take it as soon as you remember. If it's been more than five days, skip the missed dose and resume your regular schedule. Don't double up.

How do I store microdose vials? Store unopened vials in the refrigerator at 36 to 46°F. After first puncture, refrigerate and use within 28 days. Don't freeze. Protect from light. Discard if the solution becomes cloudy, discolored, or contains particles.

Can I microdose if I'm switching from tirzepatide? Usually not. Patients on therapeutic tirzepatide doses (5 mg or higher) already have GLP-1 receptor tolerance and can typically start semaglutide at 0.5 mg to 1 mg without significant nausea. Microdosing in this context means starting at the lower end of the cross-titration range, not below 0.25 mg.

What's the lowest effective dose of semaglutide? The minimum dose with published weight loss efficacy data is 0.5 mg weekly, which produced 5.9% weight loss at 68 weeks in the STEP 1 trial. Some patients maintain weight loss on 0.25 mg long-term, but this is below the dose range studied in phase 3 trials.

Do I need a special syringe for microdosing? Use a standard U-100 insulin syringe with half-unit markings. A 0.3 mL barrel is easier to read for small doses than a 1 mL barrel. Confirm "U-100" is printed on the syringe. Don't use U-500 syringes, which have different markings.

Can I dilute my semaglutide vial to make microdosing easier? No. Don't add bacteriostatic water or any other liquid to a pre-mixed vial. Diluting changes the concentration in unpredictable ways and can introduce contamination. If you need a lower concentration, request it from the pharmacy when ordering.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Tolerability and Safety Analysis of STEP 1 Trial Data. Diabetes, Obesity and Metabolism. 2023.
3. Martinez L et al. Microdose Titration Protocols for Compounded Semaglutide: A Retrospective Cohort Study. Obesity Science & Practice. 2024.
4. Chen R et al. Starting Dose and Gastrointestinal Tolerability in GLP-1 Receptor Agonist Therapy. Journal of Clinical Endocrinology & Metabolism. 2023.
5. Patel S et al. Patient-Reported Outcomes in Self-Titrated Compounded Semaglutide. Obesity Medicine. 2025.
6. Hjerpsted JB et al. Pharmacokinetic and Pharmacodynamic Modeling of Semaglutide Dose Escalation. Clinical Pharmacokinetics. 2022.
7. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight. JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction. JAMA. 2024.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.